Robyn Karnauskas
Stock Analyst at Truist Securities
(1.90)
# 3,106
Out of 4,944 analysts
183
Total ratings
42.04%
Success rate
-1.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robyn Karnauskas
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABCL AbCellera Biologics | Maintains: Buy | $28 → $10 | $4.58 | +118.34% | 2 | May 16, 2025 | |
| AMGN Amgen | Maintains: Hold | $333 → $298 | $289.33 | +3.00% | 12 | Jan 8, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Buy | $62 → $65 | $47.85 | +35.84% | 2 | Jan 8, 2025 | |
| MRK Merck & Co. | Downgrades: Hold | $130 → $110 | $82.71 | +32.99% | 11 | Jan 8, 2025 | |
| GILD Gilead Sciences | Maintains: Hold | $82 → $83 | $120.14 | -30.91% | 18 | Aug 15, 2024 | |
| ABBV AbbVie | Reiterates: Buy | $195 → $210 | $201.47 | +4.23% | 8 | Jul 26, 2024 | |
| BMEA Biomea Fusion | Downgrades: Hold | n/a | $1.72 | - | 3 | Jun 11, 2024 | |
| BIIB Biogen | Maintains: Buy | $340 | $135.19 | +151.50% | 17 | May 16, 2024 | |
| CRIS Curis | Maintains: Buy | $26 | $1.77 | +1,368.93% | 2 | May 15, 2024 | |
| CHRS Coherus Oncology | Maintains: Buy | $8 → $7 | $1.00 | +600.70% | 13 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,135 | $561.55 | +102.12% | 16 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $2.05 | +387.80% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $3.12 | +188.46% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $74 | $22.22 | +233.03% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $11.96 | +92.31% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $15.89 | +202.08% | 5 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $10.06 | +397.02% | 8 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $850 | $660.49 | +28.69% | 4 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $456 → $508 | $395.92 | +28.31% | 13 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $36 | $25.16 | +43.08% | 5 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $25 | $48.17 | -48.10% | 1 | Oct 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $5.60 | - | 6 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $140 | $58.30 | +140.14% | 5 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30,000 | $4.55 | +659,240.66% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Hold | $7 | $1.13 | +519.47% | 3 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $14.60 | +276.71% | 1 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $5.14 | - | 4 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $320 | $26.97 | +1,086.50% | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $8.62 | +74.01% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.41 | +633.14% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $85 | $0.45 | +18,726.14% | 1 | Oct 8, 2020 |
AbCellera Biologics
May 16, 2025
Maintains: Buy
Price Target: $28 → $10
Current: $4.58
Upside: +118.34%
Amgen
Jan 8, 2025
Maintains: Hold
Price Target: $333 → $298
Current: $289.33
Upside: +3.00%
Bristol-Myers Squibb Company
Jan 8, 2025
Maintains: Buy
Price Target: $62 → $65
Current: $47.85
Upside: +35.84%
Merck & Co.
Jan 8, 2025
Downgrades: Hold
Price Target: $130 → $110
Current: $82.71
Upside: +32.99%
Gilead Sciences
Aug 15, 2024
Maintains: Hold
Price Target: $82 → $83
Current: $120.14
Upside: -30.91%
AbbVie
Jul 26, 2024
Reiterates: Buy
Price Target: $195 → $210
Current: $201.47
Upside: +4.23%
Biomea Fusion
Jun 11, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.72
Upside: -
Biogen
May 16, 2024
Maintains: Buy
Price Target: $340
Current: $135.19
Upside: +151.50%
Curis
May 15, 2024
Maintains: Buy
Price Target: $26
Current: $1.77
Upside: +1,368.93%
Coherus Oncology
May 13, 2024
Maintains: Buy
Price Target: $8 → $7
Current: $1.00
Upside: +600.70%
Apr 3, 2024
Maintains: Buy
Price Target: $1,135
Current: $561.55
Upside: +102.12%
Mar 26, 2024
Maintains: Buy
Price Target: $10
Current: $2.05
Upside: +387.80%
Mar 26, 2024
Maintains: Buy
Price Target: $9
Current: $3.12
Upside: +188.46%
Mar 25, 2024
Reiterates: Buy
Price Target: $74
Current: $22.22
Upside: +233.03%
Mar 25, 2024
Reiterates: Buy
Price Target: $23
Current: $11.96
Upside: +92.31%
Mar 25, 2024
Reiterates: Buy
Price Target: $48
Current: $15.89
Upside: +202.08%
Mar 25, 2024
Reiterates: Buy
Price Target: $50
Current: $10.06
Upside: +397.02%
Mar 22, 2024
Reiterates: Buy
Price Target: $850
Current: $660.49
Upside: +28.69%
Jan 31, 2024
Maintains: Buy
Price Target: $456 → $508
Current: $395.92
Upside: +28.31%
Dec 14, 2023
Maintains: Buy
Price Target: $42 → $36
Current: $25.16
Upside: +43.08%
Oct 6, 2023
Downgrades: Hold
Price Target: $25
Current: $48.17
Upside: -48.10%
Oct 5, 2023
Downgrades: Hold
Price Target: n/a
Current: $5.60
Upside: -
Sep 25, 2023
Reiterates: Buy
Price Target: $140
Current: $58.30
Upside: +140.14%
Sep 6, 2023
Reiterates: Buy
Price Target: $30,000
Current: $4.55
Upside: +659,240.66%
Aug 16, 2023
Reiterates: Hold
Price Target: $7
Current: $1.13
Upside: +519.47%
May 11, 2023
Maintains: Buy
Price Target: $65 → $55
Current: $14.60
Upside: +276.71%
Dec 6, 2022
Downgrades: Hold
Price Target: n/a
Current: $5.14
Upside: -
Aug 23, 2022
Maintains: Buy
Price Target: $500 → $320
Current: $26.97
Upside: +1,086.50%
Aug 9, 2022
Maintains: Buy
Price Target: $10 → $15
Current: $8.62
Upside: +74.01%
Nov 11, 2020
Initiates: Buy
Price Target: $25
Current: $3.41
Upside: +633.14%
Oct 8, 2020
Initiates: Buy
Price Target: $85
Current: $0.45
Upside: +18,726.14%